Evaluating Shareholder Deals: Are APLS, CNTA, and KZR Meeting Expectations? This article investigates whether recent sales of APLS, CNTA, and KZR are providing fair compensation to their shareholders, highlighting potential legal challenges.

Evaluating Shareholder Deals: Are APLS, CNTA, and KZR Meeting Expectations? #USA #New_York #KZR #CNTA #APLS

Class Action Firm Investigates Multiple Mergers: KZR, CNTA, AFBI, and APLS The M&A Class Action Firm is currently looking into mergers involving Kezar Life Sciences, Centessa Pharmaceuticals, Affinity Bancshares, and Apellis Pharmaceuticals, offering insights into shareholder rights.

Class Action Firm Investigates Multiple Mergers: KZR, CNTA, AFBI, and APLS #United_States #New_York #KZR #CNTA #AFBI

Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? NEW YORK, April 7, 2026

#APLS #CNTA #KORE Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders?

www.stocktitan.net/news/APLS/are-apls-kore-...

🌟#最新ニュース #市場動向 #アメリカ #ナイキ #LLY #CNTA 🌟

Original post on benzinga.com

Gold Gains Over 1%; FactSet Research Raises FY2026 Outlook US stocks rise on Tuesday, with NASDAQ up 2% and Dow up 1.37%. Communication services shares gain 2.2%, while utilities fall 0.7%. FactSet...

#APLS #CNTA #Equities #FDS #IOBT #ITRM #KIDZ #Mid-Day […]

[Original post on benzinga.com]

Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders? {"summary":"","positive":[],"negative":[],"faq":[]}

#APLS #BIRD #CNTA Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?

www.stocktitan.net/news/APLS/are-apls-cnta-...

📢 Stocks Trending NOW: #MRVL #ON #APLS #WDC #ALAB #NBIS #BFRG #MKC #KIDZ #CNTA

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders Eli Lilly (NYSE: LLY) agreed to acquire Centessa Pharmaceuticals for $38.00 cash per share plus one CVR, yielding up to $47.00 per share if regulatory milestones are met. The upfront consideration implies an aggregate equity value of ~$6.3 billion and the CVR adds potential ~$1.5 billion.The deal expands Lilly's neuroscience footprint into sleep medicine by adding Centessa's OX2R agonist portfolio, including lead candidate cleminorexton (Phase 2a) targeting narcolepsy and idiopathic hypersomnia. Closing is expected in Q3 2026, subject to shareholder, High Court and regulatory approvals.

#LLY #CNTA Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

www.stocktitan.net/news/LLY/lilly-to-acquir...

El Centro Nacional de Tecnología y Seguridad Alimentaria -ADItech- avanza en su implantación en Madrid con una nueva sede técnica — Fedit El Centro Tecnológico CNTA avanza en su implantación en Madrid con una nueva sede técnica.

El #CNTA (Centro Nacional de Tecnología y Seguridad Alimentaria) -#ADItech- avanza en su implantación en Madrid con una nueva sede técnica

➡️ fedit.com/2026/03/el-c... 🔬

#AgrupacionesFedit #CentrosTecnológicos #TransferenciaTecnológica #GeneraciónDeConocimiento

#CNTA -#ADItech- lanza la sexta edición de Food (Tech)² Challengers para impulsar soluciones #foodtech que marcarán el #futuro

➡️ fedit.com/2026/02/cnta... 🔬

#CentrosTecnológicos #AgrupacionesFedit

7 #tendencias que están redefiniendo el futuro de la #alimentación, según el Mapa de Escenarios #Foodtech 2025 de #CNTA (#ADItech)

➡️ fedit.com/2026/01/7-te... 🍽️

#AgrupacionesFedit #CentrosTecnológicos #TransferenciaTecnológica #DeepInnovation #GeneraciónDeConocimiento

PRISM M☀️RNING M☀️VERS
Pre Market Gainers:
( #ANGH) Anghami Inc. up 72%
( #ESHA) ESH Acquisitions Corp. up 59%
( #AFJK) Aimei Health Technology Co. up 51%
( #NCL) Northann Corp. up 50%
Pre Market Decliners:
( #CNTA) Centessa Pharma. Down -19%
( #MSIF) MSC Income Fund, Inc. down – 17%

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications  Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today

#CNTA Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications 

www.stocktitan.net/news/CNTA/centessa-pharm...

Trabajadores rurales: el salario cierra el año con aumento y en febrero el mínimo superará $ 1 millón La Comisión Nacional de Trabajo Agrario publicó las nuevas escalas salariales para el personal permanente de prestación continua. Hay un incremento del 2,6% en los salarios de noviembre y un 2,2% con los que se pagarán correspondientes a diciembre.

AGROALNEXT -coordinado por CNTA (ADItech)- culmina con más de 250 proyectos de I+D que impulsan la transformación del sector agroalimentario — Fedit El Centro Tecnológico CNTA coordina AGROALNEXT, que culmina con más de 250 proyectos de I+D que impulsan la transformación del sector agroalimentario.

#AGROALNEXT -coordinado por #CNTA (#ADItech)- culmina con más de 250 proyectos de I+D que impulsan la transformación del sector #agroalimentario

➡️ fedit.com/2025/12/agro... 🔬

#AgrupacionesFedit #CentrosTecnológicos #DeepInnovation #TransferenciaTecnológica #GeneraciónDeConocimiento

#CNTA #^GSPC #ea434b7c-32d6-42ec-b76e-b5d0f1ef40f5 #investing #Health #Care

Origin | Interest | Match

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares Centessa Pharmaceuticals (Nasdaq: CNTA) priced an underwritten public offering of 11,627,907 ADSs at $21.50 per ADS, generating approximately $250 million in gross proceeds before underwriting discounts, commissions and offering expenses. The company granted underwriters a 30-day option for up to 1,744,186 additional ADSs. The offering is expected to close on or about November 14, 2025, subject to customary closing conditions. The ADSs are being offered under a Form S-3 registration statement filed on September 11, 2024. Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are joint book-running managers.

#CNTA Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

www.stocktitan.net/news/CNTA/centessa-pharm...

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares Centessa Pharmaceuticals (Nasdaq: CNTA) on Nov 11, 2025 commenced an underwritten public offering of American Depositary Shares (each ADS representing one ordinary share). All ADSs are being offered by Centessa and the company intends to grant underwriters a 30-day option to purchase up to an additional 15% overallotment. The offering is subject to market and other conditions and there is no assurance it will be completed or as to final size or terms.Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are joint book-running managers; Oppenheimer, Truist Securities and LifeSci Capital are co-leads. The ADSs are offered under a Form S-3 registration statement filed Sep 11, 2024 that became automatically effective.

#CNTA Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

www.stocktitan.net/news/CNTA/centessa-pharm...

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program Centessa Pharmaceuticals (Nasdaq: CNTA) reported Q3 2025 results and clinical updates on its orexin receptor 2 (OX2R) agonist program on November 5, 2025. The company reported $349.0M in cash, cash equivalents and investments as of September 30, 2025, expected to fund operations into mid-2027. Centessa disclosed Phase 2a interim data for ORX750 (55 participants across NT1, NT2, IH) showing statistically significant, dose-dependent improvements on the MWT, ESS and weekly cataplexy rate (example: NT1 1.5 mg cohort, >20 minute MWT change, p=0.0026; 87% WCR reduction, p=0.0025). ORX142 Phase 1 (89 volunteers) showed significant MWT improvements. Company expects to initiate ORX750 registrational program and ORX142/ORX489 patient studies in Q1 2026. Q3 R&D was $41.6M; net loss was $54.9M.

#CNTA Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

www.stocktitan.net/news/CNTA/centessa-pharm...

Nueva escala salarial para los trabajadores rurales De acuerdo a lo que comunicó la Unión Argentina de Trabajadores Rurales y Estibadores (UATRE), el entendimiento establece que el salario para el mes de septiembre de 2025 asciende a...

Más aumentos para trabajadores rurales: las nuevas escalas salariales, con un mínimo de $ 904.903 La Comisión Nacional de Trabajo Agrario dio a conocer las remuneraciones que se aplicarán para el trimestre septiembre-noviembre, y que permanecerán hasta tanto se dicte una nueva actualización.

Más aumentos para trabajadores rurales: las nuevas escalas salariales, con un mínimo de $ 904.903 La Comisión Nacional de Trabajo Agrario dio a conocer las remuneraciones que se aplicarán para el trimestre septiembre-noviembre, y que permanecerán hasta tanto se dicte una nueva actualización.

Más aumentos para trabajadores rurales: las nuevas escalas salariales, con un mínimo de $ 904.903 La Comisión Nacional de Trabajo Agrario dio a conocer las remuneraciones que se aplicarán para el trimestre septiembre-noviembre, y que permanecerán hasta tanto se dicte una nueva actualización.

Leading Indicators, Monday August 18, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Mon Sept 22nd - #VRAR #TASK #PLUG #LPRO #KOD #ECX #CNTA #ABAT #MTAL #KLG #EAF #AMPY - More: crystalequityresearch.com/leading-indi... - #smallcap

#TRANSFERENCIA | La Estación Experimental 'Las Palmerillas' de #Cajamar acoge hoy la jornada 'Del reto a la innovación: IV y V gama para transformar el futuro de la #alimentación', con la colaboración del #CNTA

www.plataformatierra.es/formacion/de...

Somos #EspecialistasAGRO

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all

#CNTA Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

www.stocktitan.net/news/CNTA/centessa-pharm...

Centessa Pipeline Advances: Key Sleep Disorder Drug Shows Promise, Multiple Data Readouts Coming in 2025 Centessa reports $424.9M cash runway into 2027, advancing three potential best-in-class sleep disorder treatments. See upcoming trial results timeline.

#CNTA Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

www.stocktitan.net/news/CNTA/centessa-pharm...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#KC, #RDDT, #CNTA, #CORZ, #DOCS

#OptionFlow #OptionsTrading #Trading

Centessa's Sleep Disorder Drug Shows Promise: Q4 Reveals $482M War Chest for Pipeline Expansion Phase 1 success for narcolepsy drug ORX750, robust $482M cash runway into 2027, and advancing pipeline highlight Centessa's Q4 results. Full analysis inside.

#CNTA Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

www.stocktitan.net/news/CNTA/centessa-pharm...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SGMO, #NBIS, #SMR, #CVNA, #CNTA

#OptionFlow #OptionsTrading #Trading